Limited validity of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis

Table 1 Characterization of patients

Characteristic	UC	PSC-UC	P value
Patients	29	30
Male sex	16 (55)	23 (77)	0.10
Age in years	43.2 ± 12.5	37.2 ± 2.9	0.07
Duration of disease in years	12.9 ± 10.6	10.6 ± 6.9	0.62
pANCA positive	14 (48)	16 (53)	0.8
Portal hypertension	0	0
Cholecystectomy	1 (3)	1 (3)
BMI in a.u.	25.1 ± 4.1	23.5 ± 4.2	0.1
Corticosteroids	10 (34)	10 (33)
Mesalamine	12 (41)	20 (66)
Mesalamine and immunomodulators	12 (41)	9 (30)
Biological treatment	5 (17)	0
Ursodeoxycholic acid	0	30 (100)
Fecal calprotectin in μg/g, median (95%CI)	478 (263–917)	96 (60-231)	< 0.001

Data are expressed as n (%) or mean ± standard deviation, unless otherwise indicated. a.u.: Arbitrary units; BMI: Body mass index; CI: Confidence interval; pANCA: Perinuclear anti-neutrophil cytoplasm autoantibodies; PSC-UC: Primary sclerosing cholangitis with concomitant ulcerative colitis; UC: Ulcerative colitis.